TransMedics Group, Inc. (TMDX) EV/EBITDA Ratio: 23.28x
Is TransMedics Group, Inc.’s EV/EBITDA ratio high or low?
TransMedics Group, Inc.'s EV/EBITDA ratio of 23.28x is 76% below its 2-year average of 98.12x, near the low end of its 2-year range (18.94x–429.34x).
As of Saturday, June 20, 2026. 40.00% below its 12-month average of 38.80x.
TMDX EV/EBITDA Ratio Chart
TMDX Average EV/EBITDA Ratio Chart
TMDX Current vs Average EV/EBITDA Ratio Chart
TMDX EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
23.28x
EV/EBITDA RATIO AVG TTM
38.80x
EV/EBITDA RATIO AVG 3Y
N/A
EV/EBITDA RATIO AVG 5Y
N/A
EV/EBITDA RATIO AVG 10Y
N/A
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-40.00%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TMDX Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.72B | 23.28x | 38.80x | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | N/A | 45.04x | 33.13x | 30.20x |
| 23andMe Holding Co. (ME)vs › | $15.31M | N/A | N/A | N/A | N/A |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 18.06x | 12.03x | 61.41x | 32.91x |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | 299.75x | 79.82x | 129.24x | 129.24x |
| Tempus AI, Inc. (TEM)vs › | $8.87B | N/A | N/A | N/A | N/A |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | 41.03x | 24.81x | 17.52x | 18.54x |
| Baxter International Inc. (BAX)vs › | $10.27B | 24.27x | 20.36x | 19.15x | 19.13x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | N/A | 21.34x | 19.40x | 19.09x |
| Revvity, Inc. (RVTY)vs › | $11.16B | 17.70x | 17.09x | 19.85x | 18.23x |
EV/EBITDA vs. its own history
At 23.3, EV/EBITDA is cheaper than usual, sitting higher than 6% of its 2-year history.
2-year low
18.9
median
43.8
2-year high
429.3
TransMedics Group, Inc. EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
TransMedics Group, Inc. EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for TransMedics Group, Inc. (TMDX)?
- The EV/EBITDA ratio for TMDX stock is 23.28x.
- Is TransMedics Group, Inc.'s EV/EBITDA ratio high or low?
- TransMedics Group, Inc.'s EV/EBITDA ratio of 23.28x is 76% below its 2-year average of 98.12x, near the low end of its 2-year range (18.94x–429.34x).
- What is the TTM average EV/EBITDA ratio for TransMedics Group, Inc. (TMDX)?
- The TTM average EV/EBITDA ratio for TMDX stock is 38.80x.
TransMedics Group, Inc. EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-18 | 23.28x |
| 2026-06-17 | 21.84x |
| 2026-06-16 | 22.51x |
| 2026-06-15 | 22.43x |
| 2026-06-12 | 21.76x |
| 2026-06-11 | 21.94x |
| 2026-06-10 | 22.24x |
| 2026-06-09 | 22.12x |
| 2026-06-08 | 21.30x |
| 2026-06-05 | 20.86x |
| 2026-06-04 | 21.36x |
| 2026-06-03 | 20.93x |
| 2026-06-02 | 20.60x |
| 2026-06-01 | 20.37x |
| 2026-05-29 | 20.28x |
| 2026-05-28 | 20.44x |
| 2026-05-27 | 21.04x |
| 2026-05-26 | 21.13x |
| 2026-05-22 | 20.73x |
| 2026-05-21 | 20.71x |
| 2026-05-20 | 20.49x |
| 2026-05-19 | 20.00x |
| 2026-05-18 | 20.58x |
| 2026-05-15 | 19.24x |
| 2026-05-14 | 18.94x |
| 2026-05-13 | 19.50x |
| 2026-05-12 | 19.43x |
| 2026-05-11 | 19.53x |
| 2026-05-08 | 20.45x |
| 2026-05-07 | 21.76x |
| 2026-05-06 | 21.76x |
| 2026-05-05 | 27.46x |
| 2026-05-04 | 26.63x |
| 2026-05-01 | 27.44x |
| 2026-04-30 | 27.65x |
| 2026-04-29 | 27.04x |
| 2026-04-28 | 27.78x |
| 2026-04-27 | 29.68x |
| 2026-04-24 | 30.45x |
| 2026-04-23 | 31.08x |
| 2026-04-22 | 31.48x |
| 2026-04-21 | 29.89x |
| 2026-04-20 | 31.06x |
| 2026-04-17 | 31.81x |
| 2026-04-16 | 29.95x |
| 2026-04-15 | 31.88x |
| 2026-04-14 | 31.76x |
| 2026-04-13 | 31.12x |
| 2026-04-10 | 31.30x |
| 2026-04-09 | 29.97x |
| 2026-04-08 | 30.02x |
| 2026-04-07 | 29.45x |
| 2026-04-06 | 28.76x |
| 2026-04-02 | 27.63x |
| 2026-04-01 | 27.55x |
| 2026-03-31 | 27.27x |
| 2026-03-30 | 25.87x |
| 2026-03-27 | 27.18x |
| 2026-03-26 | 28.04x |
| 2026-03-25 | 28.85x |
| 2026-03-24 | 29.90x |
| 2026-03-23 | 30.77x |
| 2026-03-20 | 31.27x |
| 2026-03-19 | 31.22x |
| 2026-03-18 | 31.08x |
| 2026-03-17 | 34.25x |
| 2026-03-16 | 34.25x |
| 2026-03-13 | 33.91x |
| 2026-03-12 | 33.31x |
| 2026-03-11 | 35.42x |
| 2026-03-10 | 35.94x |
| 2026-03-09 | 37.02x |
| 2026-03-06 | 35.60x |
| 2026-03-05 | 38.48x |
| 2026-03-04 | 40.57x |
| 2026-03-03 | 40.67x |
| 2026-03-02 | 40.39x |
| 2026-02-27 | 39.91x |
| 2026-02-26 | 36.97x |
| 2026-02-25 | 36.22x |
| 2026-02-24 | 37.85x |
| 2026-02-23 | 41.88x |
| 2026-02-20 | 41.76x |
| 2026-02-19 | 41.34x |
| 2026-02-18 | 42.14x |
| 2026-02-17 | 41.63x |
| 2026-02-13 | 40.40x |
| 2026-02-12 | 39.99x |
| 2026-02-11 | 41.47x |
| 2026-02-10 | 43.31x |
| 2026-02-09 | 42.40x |
| 2026-02-06 | 42.01x |
| 2026-02-05 | 40.33x |
| 2026-02-04 | 40.56x |
| 2026-02-03 | 42.21x |
| 2026-02-02 | 41.68x |
| 2026-01-30 | 41.68x |
| 2026-01-29 | 43.21x |
| 2026-01-28 | 43.84x |
| 2026-01-27 | 43.06x |
| 2026-01-26 | 43.32x |
| 2026-01-23 | 42.08x |
| 2026-01-22 | 42.94x |
| 2026-01-21 | 41.62x |
| 2026-01-20 | 44.12x |
| 2026-01-16 | 44.57x |
| 2026-01-15 | 44.67x |
| 2026-01-14 | 44.13x |
| 2026-01-13 | 44.36x |
| 2026-01-12 | 41.89x |
| 2026-01-09 | 42.63x |
| 2026-01-08 | 42.78x |
| 2026-01-07 | 42.69x |
| 2026-01-06 | 41.27x |
| 2026-01-05 | 39.30x |
| 2026-01-02 | 38.20x |
| 2025-12-31 | 37.88x |
| 2025-12-30 | 37.96x |
| 2025-12-29 | 38.31x |
| 2025-12-26 | 38.66x |
| 2025-12-24 | 39.52x |
| 2025-12-23 | 39.90x |
| 2025-12-22 | 40.25x |
| 2025-12-19 | 39.73x |
| 2025-12-18 | 37.70x |
| 2025-12-17 | 37.96x |
| 2025-12-16 | 38.92x |
| 2025-12-15 | 38.34x |
| 2025-12-12 | 39.46x |
| 2025-12-11 | 39.72x |
| 2025-12-10 | 40.82x |
| 2025-12-09 | 41.93x |
| 2025-12-08 | 42.48x |
| 2025-12-05 | 42.45x |
| 2025-12-04 | 43.11x |
| 2025-12-03 | 43.56x |
| 2025-12-02 | 44.08x |
| 2025-12-01 | 46.74x |
| 2025-11-28 | 45.47x |
| 2025-11-26 | 45.30x |
| 2025-11-25 | 45.38x |
| 2025-11-24 | 43.59x |
| 2025-11-21 | 40.74x |
| 2025-11-20 | 38.55x |
| 2025-11-19 | 41.52x |
| 2025-11-18 | 36.47x |
| 2025-11-17 | 35.34x |
| 2025-11-14 | 35.83x |
| 2025-11-13 | 36.00x |
| 2025-11-12 | 37.12x |
| 2025-11-11 | 38.03x |
| 2025-11-10 | 38.11x |
| 2025-11-07 | 37.11x |
| 2025-11-06 | 38.90x |
| 2025-11-05 | 38.74x |
| 2025-11-04 | 38.05x |
| 2025-11-03 | 38.82x |
| 2025-10-31 | 40.92x |
| 2025-10-30 | 42.23x |
| 2025-10-29 | 41.78x |
| 2025-10-28 | 48.05x |
| 2025-10-27 | 49.05x |
| 2025-10-24 | 48.35x |
| 2025-10-23 | 47.76x |
| 2025-10-22 | 44.37x |
| 2025-10-21 | 44.58x |
| 2025-10-20 | 44.50x |
| 2025-10-17 | 43.68x |
| 2025-10-16 | 42.97x |
| 2025-10-15 | 41.86x |
| 2025-10-14 | 41.36x |
| 2025-10-13 | 41.53x |
| 2025-10-10 | 39.93x |
| 2025-10-09 | 41.99x |
| 2025-10-08 | 43.83x |
| 2025-10-07 | 42.79x |
| 2025-10-06 | 42.34x |
| 2025-10-03 | 42.97x |
| 2025-10-02 | 43.11x |
| 2025-10-01 | 42.68x |
| 2025-09-30 | 41.71x |
| 2025-09-29 | 41.87x |
| 2025-09-26 | 42.31x |
| 2025-09-25 | 42.32x |
| 2025-09-24 | 43.60x |
| 2025-09-23 | 44.73x |
| 2025-09-22 | 46.40x |
| 2025-09-19 | 45.36x |
| 2025-09-18 | 44.93x |
| 2025-09-17 | 44.47x |
| 2025-09-16 | 44.23x |
| 2025-09-15 | 42.47x |
| 2025-09-12 | 42.57x |
| 2025-09-11 | 43.44x |
| 2025-09-10 | 40.11x |
| 2025-09-09 | 40.29x |
| 2025-09-08 | 39.31x |
| 2025-09-05 | 38.74x |
| 2025-09-04 | 38.76x |
| 2025-09-03 | 39.80x |
| 2025-09-02 | 41.47x |
| 2025-08-29 | 42.71x |
| 2025-08-28 | 43.35x |
| 2025-08-27 | 43.59x |
| 2025-08-26 | 42.79x |
| 2025-08-25 | 42.71x |
| 2025-08-22 | 44.48x |
| 2025-08-21 | 44.10x |
| 2025-08-20 | 45.22x |
| 2025-08-19 | 45.51x |
| 2025-08-18 | 46.58x |
| 2025-08-15 | 47.27x |
| 2025-08-14 | 48.06x |
| 2025-08-13 | 48.90x |
| 2025-08-12 | 48.57x |
| 2025-08-11 | 47.17x |
| 2025-08-08 | 42.54x |
| 2025-08-07 | 43.10x |
| 2025-08-06 | 44.10x |
| 2025-08-05 | 46.61x |
| 2025-08-04 | 47.61x |
| 2025-08-01 | 44.73x |
| 2025-07-31 | 44.16x |
| 2025-07-30 | 40.08x |
| 2025-07-29 | 51.12x |
| 2025-07-28 | 51.31x |
| 2025-07-25 | 52.65x |
| 2025-07-24 | 52.03x |
| 2025-07-23 | 53.51x |
| 2025-07-22 | 51.48x |
| 2025-07-21 | 50.55x |
| 2025-07-18 | 53.46x |
| 2025-07-17 | 54.69x |
| 2025-07-16 | 55.06x |
| 2025-07-15 | 56.16x |
| 2025-07-14 | 56.72x |
| 2025-07-11 | 54.66x |
| 2025-07-10 | 60.38x |
| 2025-07-09 | 61.14x |
| 2025-07-08 | 60.36x |
| 2025-07-07 | 60.57x |
| 2025-07-03 | 62.43x |
| 2025-07-02 | 61.74x |
| 2025-07-01 | 62.86x |
| 2025-06-30 | 64.67x |
| 2025-06-27 | 63.48x |
| 2025-06-26 | 62.84x |
| 2025-06-25 | 62.15x |
| 2025-06-24 | 64.04x |
| 2025-06-23 | 61.66x |
| 2025-06-20 | 59.82x |
| 2025-06-18 | 60.02x |
| 2025-06-17 | 65.69x |
| 2025-06-16 | 68.36x |
| 2025-06-13 | 68.79x |
| 2025-06-12 | 68.87x |
| 2025-06-11 | 68.79x |
| 2025-06-10 | 67.85x |
| 2025-06-09 | 67.18x |
| 2025-06-06 | 67.01x |
Showing the most recent 260 of 534 data points. The chart above shows the full history.
Related Metrics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein